

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

NCT06698796

Status	RECRUITING
Phase	Phase 3
Sponsor	Pfizer
Enrollment	211 participants

Key Eligibility Criteria

Inclusion (1)

- Participants that completed a qualifying study through Week 52.

Exclusion (6)

- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation.
- Previous administration with an investigational product (drug or vaccine) other than dazukibart in a qualifying study within 30 days (or as determined by the local requirement) or 5 half-lives preceding baseline in this study (whichever is longer).
- Current use of any prohibited concomitant medication(s).
- Active bacterial, viral, fungal, mycobacterial or other infections.
- Ongoing adverse event in a qualifying study or the participant has met safety monitoring criteria in a qualifying study that have not resolved.

... and 1 more (see full listing online)

Locations (22 total)

AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States
Arthritis & Rheumatology Research Institute, PLLC, Allen, Texas, United States
Nerve & Muscle Center of Texas, Houston, Texas, United States
... and 19 more locations